FIBROGEN INC (FGEN)
US31572Q8087 - Common Stock
Notable Wednesday Option Activity: FGEN, PLCE, MDB
Which stocks are moving on Wednesday?
Let's take a look at the stocks that are in motion in today's session.
Which stocks are moving on Wednesday?
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Commit To Buy FibroGen At $1, Earn 44.2% Annualized Using Options
These stocks are gapping in today's session
Gapping stocks in Wednesday's session
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated,...
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will...
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
Selling these three NASDAQ stocks might be the best option now, as they continue to show potential issues and continued weakness.
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news affecting shares on Tuesday morning!
AstraZeneca returns right to roxadustat to FibroGen (NASDAQ:FGEN)
AstraZeneca returns rights to FibroGen for roxadustat, a drug used for treating anemia related to chronic kidney disease. Read more here.
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246...
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO,...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on...
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series...
Noteworthy Monday Option Activity: KKR, FGEN, PETS
Monday Sector Leaders: Drugs, Vehicle Manufacturers
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q...
Commit To Buy FibroGen At $0.50, Earn 30% Using Options
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
please call Meichiel Keenan@650-219-6482 with any questions. ...
FibroGen to Report Third Quarter 2023 Financial Results
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November...
7 Stocks to Sell Before the Axe Falls
While an uncomfortable topic to discuss, consistent success in the market will require an objective view of stocks to sell.
FibroGen names Thane Wettig as permanent CEO (NASDAQ:FGEN)
FibroGen appoints Thane Wettig as permanent CEO, elevating him from interim CEO, following the departure of former CEO Enrique Conterno. Read more here.
Commit To Buy FibroGen At $0.50, Earn 10% Using Options